恩替卡韦治疗慢性乙型肝炎患者过程中血清白细胞介素17及白细胞介素22变化的研究  

The changes of IL-17 and IL-22 in serum during the course of ETV therapy in chronic HBV infected patients

作　　者：宋春辉[1] 杨斌[1] 陈黎明[1] 石峰[1] 

机构地区：[1]解放军第三○二医院肝病生物治疗研究中心,北京100039

出　　处：《胃肠病学和肝病学杂志》2010年第11期1047-1049,共3页Chinese Journal of Gastroenterology and Hepatology

摘　　要：目的研究恩替卡韦(ETV)治疗慢性乙型肝炎患者过程中血清白细胞介素17(IL-17)及白细胞介素22(IL-22)的变化。方法在应用ETV治疗的不同时间点抽取HBV感染患者及健康对照者静脉血,分离血清,检测血清中乙型肝炎病毒表面标志物(HBV-M)、乙型肝炎病毒核酸定量(HBV-DNA)、丙氨酸转移酶(ALT)以及血清中的IL-17和IL-22。结果应用ETV治疗后患者ALT及HBV-DNA从4周开始出现明显下降,血清中的IL-17也从4周开始出现明显升高,其后逐渐下降,而IL-22表现为在12周时明显下降,其后逐渐升高。结论 ETV在有效抑制病毒复制的同时,体内IL-17和IL-22的变化可能意味着免疫耐受的打破,可能有利于体内炎症反应的减轻。Objective To demonstrate the changes of IL-17 and IL-22 in serum during the course of ETV therapy in HBV infected patients. Methods The serum from the blood of HBV infected patients was separated. The ALT,HBV-DNA,HBV-M of patients and the IL-17 and IL-22 in the serum were tested. Results ALT and HBV-DNA of patients decreased significantly in 4th week after ETV therapy,the IL-17 in the serum increased significantly in 4th week and then decreased gradually. The IL-22 in the serum decreased in 12th week and then increased gradually. Conclusion When ETV suppressed HBV effectivly,the changes of IL-17 and IL-22 might lessen the inflammation of liver.

关 键 词：恩替卡韦 乙肝病毒 白细胞介素17 白细胞介素22 

分 类 号：R512.62[医药卫生—内科学]